These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 11187430)

  • 1. [Anesthesiological considerations in rheumatic diseases].
    Quoss A; Buurman C
    Anaesthesiol Reanim; 2000; 26(5):116-21. PubMed ID: 11187430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment methods. Nonsurgical treatment methods for diseases in multiple joints (polyarthritis).
    Scand J Rheumatol Suppl; 1999; 110():7-14. PubMed ID: 10422546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of early rheumatoid arthritis.
    Suresh E
    J Assoc Physicians India; 2007 May; 55():355-62. PubMed ID: 17844697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs in pregnancy. Rheumatological disorders.
    Østensen M
    Best Pract Res Clin Obstet Gynaecol; 2001 Dec; 15(6):953-69. PubMed ID: 11800535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment?
    Pieringer H; Stuby U; Biesenbach G
    Semin Arthritis Rheum; 2007 Apr; 36(5):278-86. PubMed ID: 17204310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "5D" Outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy.
    Capell H; McCarey D; Madhok R; Hampson R
    J Rheumatol; 2002 Oct; 29(10):2099-105. PubMed ID: 12375318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative management of rheumatoid arthritis. Areas of concern for primary care physicians.
    Lyssy KJ; Escalante A
    Postgrad Med; 1996 Feb; 99(2):191-4, 199-201, 205-6. PubMed ID: 8632966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of rheumatoid arthritis: unknown long-term effects.
    Prescrire Int; 2001 Apr; 10(52):55-61. PubMed ID: 11718162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Approximation to the cost of pharmacological treatment of rheumatoid arthritis in Spain].
    Mera Varela A; Blanco Rodríguez J; Caamaño Freire M
    An Med Interna; 2003 Mar; 20(3):114-21. PubMed ID: 12756895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F; Michaud K; Stephenson B; Doyle J
    J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease modifying antirheumatic drugs: longterm safety issues.
    Capell HA
    J Rheumatol Suppl; 2001 Jun; 62():10-5. PubMed ID: 11409152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inguinal hernia repair: anaesthesia, pain and convalescence.
    Callesen T
    Dan Med Bull; 2003 Aug; 50(3):203-18. PubMed ID: 13677240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
    Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DMARDS and infections in rheumatoid arthritis.
    Caporali R; Caprioli M; Bobbio-Pallavicini F; Montecucco C
    Autoimmun Rev; 2008 Dec; 8(2):139-43. PubMed ID: 19014871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
    Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
    Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modern treatment of rheumatoid arthritis].
    Surányi P
    Orv Hetil; 2005 Oct; 146(40):2059-65. PubMed ID: 16259334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacotherapy of rheumatoid arthritis].
    Gromnica-Ihle E
    Z Rheumatol; 2002; 61 Suppl 2():II/35-8. PubMed ID: 12491122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.